SRR4296066
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 57
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.470
- ALLOGRAFT_REJECTION+0.420
- INTERFERON_ALPHA_RESPONSE+0.400
- APICAL_SURFACE+0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
- INFLAMMATORY_RESPONSE+0.310
- IL6_JAK_STAT3_SIGNALING+0.300
- COMPLEMENT+0.290
- ANGIOGENESIS+0.280
- KRAS_SIGNALING_UP+0.280
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.400
- MYC_TARGETS_V2-0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.280
- DNA_REPAIR-0.240
- P53_PATHWAY-0.240
- MYC_TARGETS_V1-0.230
- ADIPOGENESIS-0.220
- WNT_BETA_CATENIN_SIGNALING-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.150
- CHOLESTEROL_HOMEOSTASIS-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2796 | Med | Medulloblastoma | 0.840 |
| 2 | c55bb20b-c929-42e2-be7f-8b1da7bee953 | — | — | 0.834 |
| 3 | TCGA-GV-A3QG-01A-11R-A220-07 | — | — | 0.830 |
| 4 | 69201842-6398-4509-b227-fca5bc12b08d | — | — | 0.821 |
| 5 | TCGA-55-6712-01A-11R-1858-07 | — | cohortA1 | 0.815 |
| 6 | s_150203_5b | EPN | Posterior Fossa EPN | 0.810 |
| 7 | TCGA-AO-A12D-01A-11R-A115-07 | — | C | 0.806 |
| 8 | EPT0805 | EPN | Posterior Fossa EPN | 0.804 |
| 9 | DRR168533 | — | — | 0.803 |
| 10 | c7a22797-676e-4f10-a51d-e3ee91a29a21 | — | — | 0.803 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.340 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.160 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.160 | Inavolisib | — uncovered |